Early in our history, BeiGene developed a proprietary cancer biology platform that incorporates improved models and processes for drug discovery into the new world of immuno-oncology and combination approaches to cancer treatment. Our discovery engine addresses the importance of tumour-immune system interactions and the value of primary tumour biopsies in developing new cancer models.
Understanding Cancer to Design Against It
We have built an extensive collection of novel in vitro, ex vivo and in vivo cancer models, in order to better select targets and to screen and evaluate agents that may have significant potential alone or in combination. Our cancer models also integrate elements of the human immune system, allowing us to evaluate potential drug candidates in conditions that approximate a patient’s cancer at the time of treatment. This is particularly significant when drug discovery requires evaluation not only of monotherapies but also multiple combinations and regimens targeting specific mutations while simultaneously immobilizing the defences cancer cells mount against the human immune system.
Utilizing rational drug design to identify and target the genes and proteins that drive cancer
Harnessing the human immune system in the tumour microenvironment
Combining immuno-oncology agents with targeted treatments; exploring key synergies